Search

The article focuses on the importance of recognizing severe ocular surface diseases (OSDs), such as sebaceous carcinomas, basal cell carcinomas, malignant melanomas, non-Hodgkin lymphomas, ocular cicatricial pemphigoid, and ocular graft-vs-host disease. Topics discussed include the clinical features, risk factors, and management strategies for these conditions, emphasizing the need for thorough examination and awareness of potential links between severe OSDs and cancer.

The article focuses on the recent U.S. Food and Drug Administration approvals that simplify the treatment of ocular surface disease (OSD). Topics discussed include the first dry eye treatment targeting evaporation, Miebo, which has shown significant results with minimal side effects, Xdemvy, the first drug for Demodex blepharitis, and Vevye, a cyclosporine A solution with a unique vehicle for increased bioavailability and comfort.

The article focuses on the introduction of Xdemvy, an Food and Drug Administration (FDA)-approved eye drop designed to treat Demodex blepharitis, a prevalent but often overlooked condition affecting millions of Americans. Topics include understanding Demodex blepharitis; diagnosing the condition through hallmark signs like collarettes; the unique properties and FDA approval of Xdemvy; and its efficacy and ease of use in eradicating Demodex mites and improving patients' ocular health.

The article offers information on managing Astigmatism, vision problem by using innovative intraocular lens (IOL) technology. Topics discussed include optical biometry, corneal topography, and optical coherence tomography which are useful tools for preoperative assessments; several options to correct refractive error in glasses or contact lenses, limbal relaxing incisions; and patients receive presbyopia which correcting IOLs with high expectations of visual outcomes.

The article offers information on various therapeutics that ophthalmologists should consider including Oxervate for neurotrophic keratitis, Upneeq for ptosis, and Tyrvaya for improving basal tear production. It highlights NOV03, a lipid layer enhancing topical agent for treating meibomian gland dysfunction.

The article discusses how to prevent ocular surface disease (OSD) is imperative to keeping the patients' eyes healthy. Topics include dentists use mirrors and magnifiers to closely observe the mouth, but especially the gingiva or gums; examining the eyelids, and steps necessary to prevent ocular surface disease or at least manage it properly.

The article focuses on surprise that our profession writes more prescriptions for dry eye disease (DED) than any other condition and that the vast majority of dedicated dry eye clinics are run by optometrists. Topics include the worked in this field for more than 25 years, and the share insights to help save you a few years in developing a successful and rewarding dry eye practice.

The article offers information on the intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) treatment. Topics discussed include second iteration with the advent of low-level light therapy (LLLT), a new two-step approach; Activation of fibroblasts and enhancing the synthesis of new collagen fibers by IPL; and also mentions about combined treatment of the Ocular Surface Disease Index (OSDI).

The article offers information related to the treatment of Dry eye disease (DED) which is is a chronic disease that negatively impacts quality of life comparably to other severe diseases. It mentions that the visual function-related manifestations including are important and underestimated aspects of the disease. It further explores the traditional DED treatment that has started with water-based artificial tears and topical lubricants. INSET: Treating Inflammation Only One Component of Dry Eye Therapy.

The article offers information on the dry eye therapy, nasal stimulation. Topics discussed include the parasympathetic nervous system that controls tear film homeostasis through innervation of the lacrimal functional unit which include cornea, conjunctiva, and lacrimal glands; the approach of doctors to develop nasal neurostimulation devices and pharmaceuticals; and changes meibomian gland activity and lipid layer thickness due to neurostimulation.

The article offers information on how new tools and techniques flourishing the time to expand your skill set and offerings. Topics include dry eye disease (DED) clinic were limited back had crude diagnostics, a poor understanding of the disease, a large unserved patient population and no on-label therapeutic agents.

The article discusses that to effectively manage ocular surface disease in your office, you may need to invest in a few new tools, all of which can help you better assess, diagnose and manage these patients including expression will indicate meibomian gland dysfunction, pointing to an evaporative form; meibography is extremely valuable in determining the severity of evaporative dry eye disease (DED); and other vital dyes are beneficial for assessing the conjunctiva for early DED.

The article evaluates several methods of meibomian gland dysfunction (MGD). Topics discussed include Lipiflow treatment heats the inner eyelid closest to meibomian glands and massages lids to evacuate gland contents; talks about Lid debridement, which removes keratin from the meibomian gland to the ocular surface; and mention about small, cost effective in-office treatment for MGD known as iLux.

The article discusses the 8th International Conference of the Tear Film and Ocular Surface Society (TFOS) held in Montpellier, France in September 2016. It presents views of optometrist Donald Korb on the role of contact lenses contributing to structural changes within the meibomian gland framework, leading to meibomian gland dysfunction (MGD). It mentions correlation between MGD and patients with Type 2 diabetes.

The article explores why Optometrists should embrace Meibomian gland dysfunction (MGD) therapies and lid lesion exams to care for a vast number of patients. Topics discussed include generate a multitude of patients for the practice who need ongoing care; current makeup products contain formaldehyde or formaldehyde releasing chemicals; and role in caring for ocular surface disease and lid lesions is critical from diagnosis to treatment.

The article focuses on identification and treatment of dry eye patients. Topics discussed include Allergic conjunctivitis, epithelial basement membrane dystrophies and convergence insufficiency as masqueraders of disease; talks about point-of-care testing for identifying allergic conjunctivitis; and mentions meibomian gland dysfunction devices as LipiFlow for thermal pulsation, iLux for thermal expression and Blephex for blepharoexfoliation.

The article reports on the increased risk of diseases including meibomian gland dysfunction (MGD), blepharitis and dry eye disease (DED) in patients wearing contact lenses focusing on the role of optometrists in early diagnosis of the symptoms. Topics include a decline in blink rate due to use of digital devices, osmolarity tests, and medical care of contact lens patients.

The article focuses on several key technologies that could affect the practice of optometry in 2018. Topics include the use of dental model approach of optometrists for routine preventative care such as thermal meibomian gland treatments, intense-pulsed light therapy and microblepharoexfoliation, the launch of the first ocular disease gene therapies, Luxturna, and the progress in treatments for retina disease such as the AMD with geographic atrophy or ischemic optic neuropathy.

The article focuses on the meibomian gland dysfunction (MGD). Topics include the cause and the remedies of dry eye disease, the identification and characteristics of different kind of MGD, provides the four components along with their respective treatment including obstruction, inflammation, biofilm formation and tear film instability

The article discusses dry eye and eye care. Topics include tear secretion, treatment for dry eyes and eye care providers (ECPs). Factors causing dry eye including use of digital devices, systemic diseases and aging population are mentioned. Other topics such as tear osmolarity, meibomian glands and routine check ups are also mentioned.

The article discusses the problem of contact lens dropout where patients stop using contact lenses and depicts the persistence of the dropout rate. Topics discussed include the development of meibomian gland dysfunction (MGD) and dry eye disease (DED) due to digital technology devices like smartphones and tablets and the wellness approach aimed towards contact lens patients, which include diagnostic, educational and management approaches.

The article offers information on the available treatments for meibomian gland dysfunction (MGD) in 2012. It states that liposomal spray delivers phospholipids to the tear film through the surface of closed eyes, according to a report from the International Workshop on Meibomian Gland Dysfunction. It discusses studies on the efficacy of warm compress to treat MGD. It adds that oral doxycycline may work directly on the eyelid tissue to reduce inflammation.

The article describes the case of a 54-year-old woman diagnosed with meibomianitis. After receiving dry eye treatment for months, the patient only experienced moderate improvement. Upon examination, traces of blepharitis was seen. The meibomian glands secreted a turbid discharge when expressed. In addition, plugs in the meibonian glands were seen, where lipids had solidified. As treatment, the patient was asked to use hot compresses on her eyes for 10 minutes each night for a minimum of 10 days.